Apellis Pharmaceuticals
Platform of novel therapeutic compounds for the treatment of autoimmune diseases.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $475m | Post IPO Debt | |
| Total Funding | 000k | ||
Sectoral Asset Management(exited)
Sofinnova Partners(exited)
Vivo Capital(exited)
F-Prime(exited)
Morningside(exited)
Cormorant Asset Management(exited)
Epidarex Capital(exited)
Aju IB Investment(exited)
Hillhouse Capital(exited)
venBio Partners(exited)
Sofinnova(exited)
Eight Roads Ventures(exited)
Solasta Ventures(exited)
XLerateHealth(exited)
Keyhorse Capital (KSTC)(exited)
Avoro Capital Advisors(exited)
Morningside Private Investors(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (73 %) | 13 % | 426 % | 97 % | (2 %) | 23 % | 29 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (801 %) | (775 %) | (125 %) | (20 %) | (25 %) | (2 %) | 35 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1121 %) | (865 %) | (133 %) | (25 %) | (32 %) | (7 %) | 14 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 632 % | 513 % | 89 % | 42 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.